TIDMEDX
RNS Number : 7234O
EDX Medical Group PLC
05 October 2023
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation No 596/2014
which is part of English law by virtue of the European (Withdrawal)
Act 2018, as amended. On publication of this announcement via a
regulatory information service, this information is considered to
be in the public domain.
EDX Medical signs agreement to distribute cancer genomic tests
from Guardant Health in UK and Nordic countries
EDX Medical Group plc -- EDX
5 October 2023
CAMBRIDGE, UK: EDX Medical Group plc ("EDX Medical, the
"Company" or the "Group"), a developer of innovative digital
diagnostic products and services for personalised treatment of
cancer, heart disease and infectious diseases, today announced that
it has entered into a strategic agreement with Guardant Health Inc.
(NASDAQ: GH), a leading precision oncology company, to distribute
Guardant Health's blood-based liquid biopsy tests in certain market
sectors in the U.K. and several Nordic countries.
Under the agreement, EDX Medical will distribute the
Guardant360(R) CDx test for genomic testing in advanced cancer and
the Guardant Reveal(TM) test for residual disease and recurrence
detection in early-stage cancer to the private healthcare sector in
the U.K. The company will also distribute Guardant360 CDx to public
and private sectors in Sweden, Denmark, Norway, Finland and Iceland
(Nordics).
The distribution contract with Guardant Health is another step
in EDX Medical's strategy to provide healthcare professionals with
world-class products and services to rapidly improve cancer
diagnosis, drug therapy selection, and recurrence detection,
supporting improved clinical outcomes for patients. EDX Medical
will provide a local service including optional home-based blood
sample collection.
Guardant Health is a market leader in clinical cancer
diagnostics and was the first company to receive U.S. Food and Drug
Administration (FDA) approval of a blood test for comprehensive
genomic profiling of all solid tumors.
Guardant360(R) CDx is the first FDA-approved blood test for
genomic testing, or tumour mutation profiling, across all solid
cancers. The test identifies guideline-recommended biomarkers to
help oncologists quickly match patients to targeted therapies.
Guardant Reveal(TM) is the first blood-only liquid biopsy test
that detects circulating tumour DNA (ctDNA) for minimal residual
disease (MRD) assessment in colorectal, breast, and lung cancer,
and can also be used to monitor recurrence in previously diagnosed
patients.
"Guardant has proven itself as a true pioneer in cancer genomics
and we are proud that they have selected EDX Medical as their
commercial partner for the U . K. and Nordic countries ," said
Professor Sir Chris Evans OBE, founder of EDX Medical . " The tests
that we will be distributing are outstanding in the sector and make
a tremendous difference to healthcare professionals and
patients."
Dr , Mike Hudson, chief executive of EDX Medical, said: " I 'm
delighted to be working with the scientific leaders at Guardant
Health . This agreement provides our clients with access to
world-class genomic testing products and the opportunity to join a
group of thought leaders in personalised medicine."
" Guardant Health is dedicated to helping cancer patients live
longer and healthier lives by providing healthcare professionals
with insights into the genomic factors driving tumor growth," said
Chris Freeman, Guardant Health chief commercial officer . "We look
forward to making blood-based genomic testing available to more
physicians and patients across the UK and Europe through our
relationship with EDX."
About EDX Medical Group
EDX Medical Group plc develops innovative digital diagnostic
products and services, enabling cost effective and timely delivery
of personalised treatment for cancer, heart disease and infectious
diseases. The company is listed on the AQSE Growth Market (TIDM:
EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE,
a medical and life sciences entrepreneur with more than 30 years of
experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions
combining advanced biological and digital technologies, EDX Medical
seeks to cost-effectively improve the detection and
characterisation of disease in order to personalise treatment in a
timely fashion. Early disease detection and biologically-based
personal treatment optimisation is considered to be the most
impactful way of reducing deaths and lowering the cost of
healthcare globally.
EDX Medical has established expertise in the design,
development, validation and sourcing of diagnostic testing
solutions to ISO 13485 and key laboratory tests performed by the
Company have been accredited to ISO 15189 by the United Kingdom
Accreditation Service (UKAS).
EDX Medical Group operates a molecular biology and diagnostics
laboratory in Cambridge, UK, and 100%-owned subsidiary companies,
Hutano Diagnostics Limited in Oxford, UK, and Torax Biosciences Ltd
in Ireland.
Learn more: www.edxmedical.co.uk
Contacts:
EDX Medical plc
Dr Mike Hudson (Chief Executive Officer) +44 (0)7812 345 301
Oberon Capital
Nick Lovering (Corporate Adviser)
Adam Pollock (Corporate Broking)
Mike Seabrook (Corporate Broking) +44 (0)20 3179 5300
Media House International
Ramsay Smith +44 (0)7788 414856
ramsay@mediahouse.co.uk
Gary McQueen + 44 (0)7834 694609
gary@mediahouse.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXUSSVRONURRAA
(END) Dow Jones Newswires
October 05, 2023 02:00 ET (06:00 GMT)
EDX Medical (AQSE:EDX)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
EDX Medical (AQSE:EDX)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
